Global Blood’s (GBT) NDA & sNDA for Oxbryta Get Priority Review

Posted byZacks Equity Research Leave a comment on Global Blood’s (GBT) NDA & sNDA for Oxbryta Get Priority Review

The FDA grants priority review to Global Blood’s (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pe…

Leave a comment

Your email address will not be published. Required fields are marked *